Psoriasis Clinical Trial
Official title:
A Case Control Study to Evaluate the Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) Among Patients With Psoriasis
Main objectives
1. Establish the association of psoriasis and the presence of NAFLD in the patients with
psoriasis attending dermatologic clinic center.
Secondary objective
1. Evaluate for the presence of other components metabolic syndrome in this group of
patients including hypercholesterolemia, hypertension, obesity, and insulin resistance
2. Determine if there is an association between the extent and severity of psoriasis and
the presence of NAFLD.
3. Identify an association between BMI and presence of NAFLD in people with psoriasis and
use it as a predictive index for primary screening of NAFLD in psoriatic patients.
Psoriasis is a common inflammatory disorder of the skin and in some patients the joints.
Several reports have demonstrated a possible association between psoriasis and diabetes
mellitus, obesity, hypertension, myocardial infarction, and heart failure.
Metabolic syndrome (MS) is a cluster of diabetes mellitus, hypertension, visceral obesity
and hyperlipidemia and is thought to be caused by insulin resistance and the presence of a
systemic inflammation which is evident by the increased level of inflammatory cytokines like
TNF in this group of patients.
Non Alcoholic Fatty Liver Disease ( NAFLD) is the accumulation of fat vacuoles in the
cytoplasm of hepatocytes and is believed to be the most common cause of chronic liver
disease in developed countries. Currently, the metabolic syndrome has been found to be a
strong predictor of NAFLD, and NAFLD is widely accepted to be the hepatic manifestation of
the MS.
Since people with psoriasis have significantly higher rates of metabolic syndrome and
regarding the fact that NAFLD is considered as the hepatic manifestation of MS, the purpose
of this study is to determine the prevalence of NAFLD in subjects with psoriasis compared to
the non -psoriatic population.
We have designed a case control study of patients who attend the dermatologic clinic at GWU
with a clinical diagnosis of psoriasis. By performing a limited RUQ abdominal
ultrasonography at the GWU hospital, we will be able to screen the patients with a possible
diagnosis of NAFLD. Since NAFLD is a diagnosis of exclusion, those patients who have been
screened positive for NAFLD, will be further evaluated for ruling out the other etiologies
of fatty liver such as alcohol abuse and hepatitis.
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
| Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
| Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
| Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
| Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
| Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
| Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
| Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
| Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
| Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
| Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
| Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
| Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
| Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
| Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
| Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
| Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |